文献速递糖尿病

口服胰岛素免疫治疗用于1型糖尿病高危儿童的随机对照试验

Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial.
PubMed 文献 · Diabetologia · 2021-01-30

在德国单中心开展的I/II期随机对照试验纳入44名6月龄至2.99岁、胰岛自身抗体阴性且携带易感HLA DR4-DQ8基因型的1型糖尿病一级亲属儿童,按1:1随机接受每日口服胰岛素(7.5 mg递增至67.5 mg)或安慰剂12个月。口服胰岛素耐受良好,未达到预设的免疫疗效主要终点(p=0.54);探索性分析提示易感INS基因型儿童中胰岛素治疗组抗体应答更常见。

要点

  • 口服胰岛素在遗传高危幼儿中安全耐受,未改变代谢指标。
  • 主要免疫疗效终点未达到,胰岛素与安慰剂组免疫应答比例相近。
  • 探索性分析提示易感INS基因型儿童可能产生胰岛素抗体应答。

核心结论

  • 口服胰岛素免疫治疗在遗传高危幼儿中安全,但未达到预设的免疫应答主要终点。

研究设计与样本

  • 德国单中心I/II期随机对照试验,44名6月龄至2.99岁胰岛自身抗体阴性儿童按1:1随机分组,口服胰岛素组22例、安慰剂组21例纳入分析。

主要发现

  • 口服胰岛素耐受良好,代谢指标无变化。
  • 胰岛素组免疫应答54.5%,安慰剂组66.7%,主要终点未达显著(p=0.54)。
  • 易感INS基因型儿童中胰岛素组抗体应答72.7%高于安慰剂组18.2%(p=0.03)。
  • T细胞应答受治疗无关的炎症事件影响。

关键数值与推荐

  • 口服胰岛素剂量7.5 mg起始,递增至67.5 mg,疗程12个月。

临床怎么用

  • 暂不支持在遗传高危幼儿中常规使用口服胰岛素进行免疫干预,INS基因型分层值得进一步研究。

局限性

  • 样本量小,探索性分析结果需更大样本验证,单中心设计限制外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Oral administration of antigen can induce immunological tolerance. Insulin is a key autoantigen in childhood type 1 diabetes. Here, oral insulin was given as antigen-specific immunotherapy before the onset of autoimmunity in children from age 6 months to assess its safety and immune response actions on immunity and the gut microbiome. METHODS: A phase I/II randomised controlled trial was performed in a single clinical study centre in Germany. Participants were 44 islet autoantibody-negative children aged 6 months to 2.99 years who had a first-degree relative with type 1 diabetes and a susceptible HLA DR4-DQ8-containing genotype. Children were randomised 1:1 to daily oral insulin (7.5 mg with dose escalation to 67.5 mg) or placebo for 12 months using a web-based computer system. The primary outcome was immune efficacy pre-specified as induction of antibody or T cell responses to insulin and measured in a central treatment-blinded laboratory. RESULTS: Randomisation was performed in 44 children. One child in the placebo group was withdrawn after the first study visit and data from 22 insulin-treated and 21 placebo-treated children were analysed. Oral insulin was well tolerated with no changes in metabolic variables. Immune responses to insulin were observed in children who received both insulin (54.5%) and placebo (66.7%), and the trial did not demonstrate an effect on its primary outcome (p = 0.54). In exploratory analyses, there was preliminary evidence that the immune response and gut microbiome were modified by the INS genotype Among children with the type 1 diabetes-susceptible INS genotype (n = 22), antibody responses to insulin were more frequent in insulin-treated (72.7%) as compared with placebo-treated children (18.2%; p = 0.03). T cell responses to insulin were modified by treatment-independent inflammatory episodes. CONCLUSIONS/INTERPRETATION: The study demonstrated that oral insulin immunotherapy in young genetically at-risk children was safe, but was not associated with an immune response as predefined in the trial primary outcome. Exploratory analyses suggested that antibody responses to oral insulin may occur in children with a susceptible INS genotype, and that inflammatory episodes may promote the activation of insulin-responsive T cells. TRIAL REGISTRATION: Clinicaltrials.gov NCT02547519 FUNDING: The main funding source was the German Center for Diabetes Research (DZD e.V.).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Assfalg R, Knoop J, Hoffman KL, et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia. 2021. PMID: 33515070. doi:10.1007/s00125-020-05376-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。